Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-05-10
2011-05-10
Zhou, Shubo (Joe) (Department: 1631)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C536S024100, C530S300000, C530S350000
Reexamination Certificate
active
07939646
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.
REFERENCES:
patent: 4818707 (1989-04-01), Breneman
patent: 5539084 (1996-07-01), Geysen
patent: 5759551 (1998-06-01), Ladd et al.
patent: 5776468 (1998-07-01), Hauser et al.
patent: 5785973 (1998-07-01), Bixler et al.
patent: 5786148 (1998-07-01), Bandman et al.
patent: 5846532 (1998-12-01), Kline
patent: 6090611 (2000-07-01), Covacci et al.
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6146632 (2000-11-01), Momin et al.
patent: 6252047 (2001-06-01), Billing-Medel et al.
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6329505 (2001-12-01), Xu et al.
patent: 6350452 (2002-02-01), Riss
patent: 6375952 (2002-04-01), Koelle et al.
patent: 6387888 (2002-05-01), Mincheff et al.
patent: 6620922 (2003-09-01), Xu et al.
patent: 6800746 (2004-10-01), Xu et al.
patent: 6943236 (2005-09-01), Xu et al.
patent: 7048931 (2006-05-01), Xu et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0081680 (2002-06-01), Xu et al.
patent: 2003/0185830 (2003-10-01), Xu et al.
patent: 19649207 (1996-11-01), None
patent: 317 141 (1989-05-01), None
patent: 652 014 (1995-05-01), None
patent: 936 270 (1999-08-01), None
patent: WO 93/14755 (1993-08-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 95/30758 (1995-11-01), None
patent: WO 96/21671 (1996-07-01), None
patent: WO 97/33909 (1997-09-01), None
patent: WO 98/12302 (1998-03-01), None
patent: WO 98/17687 (1998-04-01), None
patent: WO 98/20117 (1998-05-01), None
patent: WO 98/31799 (1998-07-01), None
patent: WO 98/37039 (1998-08-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/38310 (1998-09-01), None
patent: WO 98/39446 (1998-09-01), None
patent: WO 98/45435 (1998-10-01), None
patent: WO 98/50567 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/06552 (1999-02-01), None
patent: WO 99/25825 (1999-05-01), None
patent: WO 99/31236 (1999-06-01), None
patent: WO 99/67384 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/61756 (2000-10-01), None
patent: WO 01/34629 (2001-05-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 01/81577 (2001-11-01), None
Abbas, A.K. et al.,Cellular and Molecular Immunology, W.B. Saunders Company, pp. 50-52, 1991.
Ahn and Kunkel, “The structural and functional diversity of dystrophin,”Nature Genetics 3: 283-291, Apr. 1993.
Alberts, B. et al.,Molecular Biology of The Cell, Third Edition, Garland Publishing Company, New York, 1994, p. 465.
Alexeyev et al., “Improved antibiotic-resistance gene cassettes and omega elements forEscherichia colivector construction and in vitro deletion/insertion mutagenesis,”Gene 160:63-67, 1995.
Anderson, L. et al., “A comparison of selected mRNA and protein abundances in human liver,”Electrophoresis18: 533-537, 1997.
Anderson, W. F., “Human gene therapy,”Nature392(Supp): 25-30, Apr. 30, 1998.
Apostolopoulos, V. et al., “Cell-mediated immune responses to MUC1 fusion protein coupled to mannan,”Vaccine14(9): 930-938, 1996.
Aspinall, J.O. et al., “Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues,”Journal of Urology 154: 622-628, Aug. 1996.
Berthon et al., “Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43,”Am. J. Hum. Genet. 62(6):1416-1424, Jun. 1998.
Blok et al., “Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR,”The Prostate 26:213-224, 1995.
Bowie, J.U. et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247: 1306-1310, Mar. 1990.
Burgess, W. H. et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”The Journal of Cell Biology111: 2129-2138, Nov. 1990.
Busselmakers et al., Genbank Accession No. AF103907, Aug. 14, 2000.
Busselmakers et al., Genbank Accession No. AF103908, Aug. 14, 2000.
Cawthon et al., “cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene,”Genomics 9:446-460, 1991.
Chen, Q. et al., “Development of Th1-type immune responses requires the type I cytokine receptor TCCR,”Nature407: 916-920, Oct. 2000.
Chu et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity,”J. Exp. Med. 186(10): 1623-1631, Nov. 17, 1997.
Coleman et al.,Fundamental Immunology, Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
Corey et al., “Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies,”Clinical Chemistry43 (4): 575-584, 1997.
Correale et al., “Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide,”Journal of Immunology161 (6): 3186-3194, Sep. 15, 1998.
Correale et al., “In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen,”Journal of the National Cancer Institute89 (4): 293-300, Feb. 19, 1997.
Critical Synergy: The Biotechnology Industry and Intellectual Property Protection. Presentations of the Intellectual Property committee of the biotechnology Industry Organization at the Oct. 17, 1994 Hearing of the United States Patent and Trademark Office, San Diego, CA.
Database EMBL Accesion No. AA453562, Jun. 11, 1997, Hillier et al., “Homo sapiens cDNA clone 788180.”
Derwent Geneseq Database, Accession No. V58522, Dec. 8, 1998.
Derwent Geneseq Database, Accession No. V61287, Jan. 6, 1999.
Dillman, R.O., “Monoclonal antibodies for treating cancer,”Ann Intern Med111(7):592-603, 1989.
Duerst and Nees, “Nucleic acid characteristic of late or early passage cells immortalized by papilloma virusand related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervicallesions,” Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
El-Shirbiny, Prostatic Specific Antigen,Advances In Clinical Chemistry 31:99-133, 1994.
EMBL Database, Accession No. AA503963, Jul. 4, 1997.
Ezzell, C., “Cancer vaccines: an idea whose time has come?”The Journal of NIH Research 7:46-49, Jan. 1995.
Fannon, M.R., “Gene expression in normal and disease states—identification of therapeutic targets,”Trends in Biotechnology 14: 294-298, Aug. 1996.
Fu, L. et al., “Translational regulation of human p53 gene expression,”The EMBO Journal15:4392-4401, 1996.
Gao, C-L. et al., “Blinded Evaluation Of Reverse Transcriptase-Polymerase Chain Reaction Prostate-Specific Antigen Peripheral Blood Assay For Molecular Staging of Prostate Cancer,”Urology53(4): 714-721, 1999.
Garde, S.V. et al., “Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistoche
Kalos Michael D.
Stolk John A.
Xu Jiangchun
Corixa Corporation
Seed IP Law Group PLLC
Zhou Shubo (Joe)
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2622638